KOLINPHARMA® S.p.A. is proud to communicate the first patent for XINPROX®.
XINPROX®, studied and developed for the well – being of the prostate, it is a food supplement which includes in the formulation raw materials of high quality, technologically advanced and supported by scientific studies, such as pollen extract, quercetin, alpha lipoic acid and L-tryptophan.
Now, Kolinpharma has 46 patents in total, 7 in Italy, 6 in USA, 1 in Israel and 32 in the principal States of UE. Rita Paola Petrelli, president of Kolinpharma has commented: “We are proud to announce that we have achieved the first patent for Xinprox® which testifies the validity of the formulations and the work of the R&D department and of the all company. […] The research is one of our elements of strengths and for this reason, we want to continue and invest and value our product to offer to costumer – patient scientifically validated solutions, patent is synonymous of synergy, uniqueness and innovation".